A preclinical study showed that Ccm3 mice treated with anti-mouse BR3 to deplete B cells harbored smaller lesions, fewer mature CCMs [15], and decreased non-heme iron deposition, confirming the pathogenicity of the B-cell-mediated immune response in CCMs [15,22]. The gene discussed is TNFRSF13C; the disease is cerebrocostomandibular syndrome.